文献速递创伤骨科骨质疏松与代谢性骨病

老年股骨近端骨折术后的合成代谢类固醇治疗:骨密度、功能恢复与安全性的I级证据系统综述与Meta分析

Anabolic-steroid therapy after geriatric proximal femur fracture: a level I evidence systematic review and meta-analysis of bone density, functional recovery, and safety.
PubMed 文献 · Osteoporos Int · 2025-11-17

该系统综述与Meta分析纳入9项随机对照试验共466例老年髋部骨折患者,评价术后雄激素合成代谢类固醇(AAS)的疗效与安全性。AAS显著提高髋部骨密度z评分(d=1.29,95%CI 1.04-1.55;中等确定性),Harris髋关节评分(d=2.85,95%CI 2.52-3.17)与Katz日常生活活动指数(d=0.95,95%CI 0.71-1.19)亦改善,但后两者证据确定性极低。AAS组报告13例轻度一过性不良事件(13/214,6.1%),无严重雄激素相关并发症。

要点

  • 9项RCT共466例老年髋部骨折患者,214例接受合成代谢类固醇治疗。
  • AAS显著提高髋部骨密度z评分(d=1.29,95%CI 1.04-1.55;中等确定性)。
  • HHS与KADL指数改善但证据确定性极低,AAS组13/214(6.1%)出现轻度一过性不良事件。

核心结论

  • 低剂量AAS用于髋部骨折术后可提高骨密度并改善患者报告的功能,未发现显著安全性问题;但功能获益证据受限于样本量小且多未设盲的试验,需更大规模多中心RCT采用标准化治疗方案与功能终点进一步明确。

研究设计与样本

  • 系统检索MEDLINE、Embase、CENTRAL、Web of Science、Google Scholar、ClinicalTrials.gov与Wiley(建库至2025年6月1日),纳入比较AAS与安慰剂/标准治疗的随机对照试验。
  • 共纳入9项RCT、466例参与者,其中214例接受合成代谢类固醇;采用固定效应模型分析,并以GRADE系统分级证据确定性。

主要发现

  • AAS显著提高髋部骨密度z评分(d=1.29,95%CI 1.04-1.55;中等确定性)。
  • Harris髋关节评分(HHS)随合成代谢治疗改善(d=2.85,95%CI 2.52-3.17)。
  • Katz日常生活活动(KADL)指数随合成代谢治疗改善(d=0.95,95%CI 0.71-1.19)。
  • HHS与KADL指数结果因高偏倚风险与不精确性,证据确定性极低。
  • 与对侧腿相比,术侧腿肌力未见显著增益;AAS组发生13例轻度一过性不良事件(13/214,6.1%),包括肝酶升高、出汗、多毛,未报告严重雄激素相关并发症。

关键数值与推荐

  • AAS提高髋部骨密度z评分的效应量d=1.29(95%CI 1.04-1.55),证据确定性中等。
  • AAS改善HHS的效应量d=2.85(95%CI 2.52-3.17),证据确定性极低。
  • AAS改善KADL指数的效应量d=0.95(95%CI 0.71-1.19),证据确定性极低。
  • AAS组轻度一过性不良事件13/214(6.1%),无严重雄激素相关并发症。

临床怎么用

  • 原文结论认为低剂量AAS用于髋部骨折术后可提高骨密度并改善患者报告的功能,未发现显著安全性问题。
  • 原文指出功能获益证据受限于样本量小且多未设盲的试验,需更大规模多中心RCT采用标准化治疗方案与功能终点进一步明确AAS的获益。

局限性

  • 功能获益证据受限于样本量小且多未设盲的试验。
  • HHS与KADL指数结果因高偏倚风险与不精确性,证据确定性极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Older adults often face rapid loss of bone and muscle after a hip fracture, which can hinder recovery and independence. Anabolic steroid therapy increased bone mineral density and enhanced functional performance without notable side effects, showing potential as an adjunct to rehabilitation to support musculoskeletal recovery in postoperative elderly patients. INTRODUCTION: Proximal femur ("hip") fractures are associated with high complication rates and challenging rehabilitation courses in the geriatric population. These patients can develop rapid sarcopenia and bone loss. Anabolic agents such as androgenic anabolic steroids (AAS) might counteract this catabolic state, but their efficacy remains uncertain. The purpose of this systematic review and meta-analysis was to evaluate whether postoperative AAS improves the outcomes in geriatric hip fractures. METHODS: A systematic search of MEDLINE, Embase, CENTRAL, Web of Science, Google Scholar, ClinicalTrials.gov, and Wiley (inception to June 1, 2025) identified randomized controlled trials (RCTs) comparing an AAS with placebo/standard care after hip fracture. After record screening and data extraction, the data from studies evaluating AAS were analyzed using fixed-effect modeling. In addition, studies were assessed descriptively. The certainty of evidence was graded using the GRADE system. RESULTS: Nine RCTs (466 total participants; 214 received anabolic agents) met the inclusion criteria. AAS therapy significantly increased hip bone mineral density (BMD) z-score (d = 1.29, 95% CI 1.04-1.55; moderate certainty). The Harris Hip Score (HHS) (d = 2.85, 95% CI 2.52-3.17) and Katz Activities of Daily Living (KADL) index (d = 0.95, 95% CI 0.71-1.19) also improved with anabolic therapy. HHS and KADL index findings had very low certainty due to a high risk of bias and imprecision. No significant gain was observed in operative-leg strength versus the contralateral leg. Thirteen mild, transient adverse events (liver-enzyme elevation, sweating, hirsutism) occurred among AAS patients (13/214, 6.1%). No serious androgen-related complications were reported. CONCLUSION: Low-dose AAS after hip fracture surgery increased BMD and improved patient-reported function without significant safety concerns. Still, evidence of functional benefits is limited by small, often unblinded trials. Larger, multicenter RCTs using standardized treatment protocols and functional endpoints will help better determine the benefits of AAS after proximal femur fractures. LEVEL OF EVIDENCE: Level I, Systematic Review and Meta-analysis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Box MW, O'Connor KP, Major J, et al. Anabolic-steroid therapy after geriatric proximal femur fracture: a level I evidence systematic review and meta-analysis of bone density, functional recovery, and safety. Osteoporos Int. 2025. PMID: 41249634. doi:10.1007/s00198-025-07762-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。